Recap: Zynex Q2 Earnings

Shares of Zynex ZYXI increased 2.65% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 50.00% year over year to $0.09, which were in line with the estimate of $0.09.

Revenue of $19,263,000 up by 87.07% year over year, which beat the estimate of $19,120,000.

Guidance

Zynex hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Jul 28, 2020

Time: 04:15 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1487/36138

Recent Stock Performance

Company's 52-week high was at $29.73

Company's 52-week low was at $7.51

Price action over last quarter: Up 15.12%

Company Overview

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.